Genomic surveillance of malaria parasites in an indigenous community in the Peruvian Amazon.

Luis Cabrera-Sosa, Oscar Nolasco, Johanna H Kattenberg, Carlos Fernandez-Miñope, Hugo O Valdivia, Keare Barazorda, Silvia Arévalo de Los Rios, Hugo Rodriguez-Ferrucci, Joseph M Vinetz, Anna Rosanas-Urgell, Jean-Pierre Van Geertruyden, Dionicia Gamboa, Christopher Delgado-Ratto
Author Information
  1. Luis Cabrera-Sosa: Laboratorio de Malaria: Parásitos y Vectores, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias e Ingeniería, Universidad Peruana Cayetano Heredia, Lima, Peru. luis.cabrera@upch.pe.
  2. Oscar Nolasco: Laboratorio de Malaria: Parásitos y Vectores, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias e Ingeniería, Universidad Peruana Cayetano Heredia, Lima, Peru.
  3. Johanna H Kattenberg: Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
  4. Carlos Fernandez-Miñope: Instituto de Medicina Tropical "Alexander Von Humboldt", Universidad Peruana Cayetano Heredia, Lima, Peru.
  5. Hugo O Valdivia: Department of Parasitology, U.S. Naval Medical Research Unit SOUTH (NAMRU SOUTH), Lima, Peru.
  6. Keare Barazorda: Department of Parasitology, U.S. Naval Medical Research Unit SOUTH (NAMRU SOUTH), Lima, Peru.
  7. Silvia Arévalo de Los Rios: Laboratorio de Salud Pública de Loreto, Gerencia Regional de Salud de Loreto, Iquitos, Loreto, Peru.
  8. Hugo Rodriguez-Ferrucci: Facultad de Medicina Humana, Universidad Nacional de la Amazonía Peruana, Iquitos, Loreto, Peru.
  9. Joseph M Vinetz: Instituto de Medicina Tropical "Alexander Von Humboldt", Universidad Peruana Cayetano Heredia, Lima, Peru.
  10. Anna Rosanas-Urgell: Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
  11. Jean-Pierre Van Geertruyden: Malaria Research Group (MaRch), Global Health Institute (GHI), Family Medicine and Population Health Department (FAMPOP), Faculty of Medicine, University of Antwerp, Antwerp, Belgium.
  12. Dionicia Gamboa: Laboratorio de Malaria: Parásitos y Vectores, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias e Ingeniería, Universidad Peruana Cayetano Heredia, Lima, Peru.
  13. Christopher Delgado-Ratto: Instituto de Medicina Tropical "Alexander Von Humboldt", Universidad Peruana Cayetano Heredia, Lima, Peru. chris.delgadoratto@uantwerpen.be.

Abstract

Hard-to-reach communities represent Peru's main challenge for malaria elimination, but information about transmission in these areas is scarce. Here, we assessed Plasmodium vivax (Pv) and P. falciparum (Pf) transmission dynamics, resistance markers, and Pf hrp2/3 deletions in Nueva Jerusalén (NJ), a remote, indigenous community in the Peruvian Amazon with high population mobility. We collected samples from November 2019 to May 2020 by active (ACD) and passive case detection (PCD) in NJ. Parasites were identified with microscopy and PCR. Then, we analyzed a representative set of positive-PCR samples (Pv = 68, Pf = 58) using highly-multiplexed deep sequencing assays (AmpliSeq) and compared NJ parasites with ones from other remote Peruvian areas using population genetics indexes. The ACD intervention did not reduce malaria cases in the short term, and persistent malaria transmission was observed (at least one Pv infection was detected in 96% of the study days). In Nueva Jerusalen, the Pv population had modest genetic diversity (He = 0.27). Pf population had lower diversity (He = 0.08) and presented temporal clustering, one of these clusters linked to an outbreak in February 2020. Moreover, Pv and Pf parasites from NJ exhibited variable levels of differentiation (Pv Fst = 0.07-0.52 and Pf Fst = 0.11-0.58) with parasites from other remote areas. No artemisin resistance mutations but chloroquine (57%) and sulfadoxine-pyrimethamine (35-67%) were detected in NJ's Pf parasites. Moreover, pfhrp2/3 gene deletions were common (32-50% of parasites with one or both genes deleted). The persistent Pv transmission and the detection of a Pf outbreak with parasites genetically distinct from the local ones highlight the need for tailored interventions focusing on mobility patterns and imported infections in remote areas to eliminate malaria in the Peruvian Amazon.

Keywords

References

  1. PLoS One. 2011;6(9):e23486 [PMID: 21949680]
  2. Sci Rep. 2023 Nov 13;13(1):19779 [PMID: 37957271]
  3. Biomedica. 2023 Sep 30;43(3):352-359 [PMID: 37871569]
  4. Malar J. 2020 Dec 4;19(1):450 [PMID: 33276776]
  5. PLoS Genet. 2018 May 23;14(5):e1007279 [PMID: 29791438]
  6. Lancet Infect Dis. 2018 Aug;18(8):874-883 [PMID: 29909069]
  7. Microb Genom. 2016 Nov 30;2(11):e000093 [PMID: 28348833]
  8. Sci Rep. 2017 Aug 14;7(1):8082 [PMID: 28808240]
  9. PLoS Med. 2021 Apr 23;18(4):e1003560 [PMID: 33891580]
  10. Bioinformatics. 2009 Jul 15;25(14):1754-60 [PMID: 19451168]
  11. Pathogens. 2021 Nov 04;10(11): [PMID: 34832588]
  12. Lancet Reg Health Am. 2022 May;9: [PMID: 35663000]
  13. Malar J. 2022 Oct 21;21(1):297 [PMID: 36271383]
  14. Mol Cell. 2000 Oct;6(4):861-71 [PMID: 11090624]
  15. J Clin Microbiol. 2005 May;43(5):2435-40 [PMID: 15872277]
  16. PLoS One. 2016 Sep 16;11(9):e0163137 [PMID: 27636709]
  17. Malar J. 2019 May 7;18(1):163 [PMID: 31064369]
  18. PLoS One. 2015 Jul 07;10(7):e0131576 [PMID: 26151448]
  19. Sci Rep. 2020 Feb 28;10(1):3756 [PMID: 32111872]
  20. Antimicrob Agents Chemother. 2009 May;53(5):2042-51 [PMID: 19258269]
  21. Genome Res. 2010 Sep;20(9):1297-303 [PMID: 20644199]
  22. Sci Rep. 2022 Oct 1;12(1):16474 [PMID: 36182962]
  23. Wellcome Open Res. 2023 Jan 16;8:22 [PMID: 36864926]
  24. Bioinformatics. 2014 Aug 1;30(15):2114-20 [PMID: 24695404]
  25. Rev Peru Med Exp Salud Publica. 2018 Jul-Sep;35(3):497-504 [PMID: 30517511]
  26. J Clin Microbiol. 2004 Dec;42(12):5636-43 [PMID: 15583293]
  27. Heliyon. 2020 May 18;6(5):e03964 [PMID: 32885059]
  28. Malar J. 2005 Feb 11;4:11 [PMID: 15707493]
  29. Malar J. 2022 Oct 28;21(1):306 [PMID: 36307852]
  30. Emerg Infect Dis. 2015 May;21(5):797-803 [PMID: 25897626]
  31. PLoS Negl Trop Dis. 2020 Oct 28;14(10):e0008808 [PMID: 33112884]
  32. Microbiol Spectr. 2023 Feb 22;:e0096022 [PMID: 36840586]
  33. Bioinformatics. 2019 Feb 1;35(3):526-528 [PMID: 30016406]
  34. PLoS Negl Trop Dis. 2022 May 9;16(5):e0010415 [PMID: 35533146]
  35. Pathog Glob Health. 2015 May;109(3):142-52 [PMID: 25891915]
  36. Malar J. 2020 Nov 30;19(1):439 [PMID: 33256739]
  37. Pathogens. 2021 Mar 02;10(3): [PMID: 33801386]
  38. Int J Infect Dis. 2021 Apr;105:293-297 [PMID: 33596478]
  39. N Engl J Med. 2019 Jan 17;380(3):229-241 [PMID: 30650326]
  40. Rev Soc Bras Med Trop. 2019 Feb 21;52:e20180225 [PMID: 30810653]
  41. Bioinformatics. 2011 Nov 1;27(21):3070-1 [PMID: 21926124]
  42. N Engl J Med. 2019 Jan 17;380(3):215-228 [PMID: 30650322]
  43. Malar J. 2020 Nov 11;19(1):404 [PMID: 33176792]
  44. Am J Trop Med Hyg. 2016 Jan;94(1):128-31 [PMID: 26483121]
  45. PLoS One. 2010 Jan 25;5(1):e8091 [PMID: 20111602]
  46. Front Cell Infect Microbiol. 2021 Sep 21;11:742681 [PMID: 34621693]
  47. Int J Environ Res Public Health. 2020 Dec 26;18(1): [PMID: 33375379]
  48. J Antimicrob Chemother. 2021 Oct 11;76(11):2854-2862 [PMID: 34379746]
  49. Science. 1999 Nov 12;286(5443):1351-3 [PMID: 10558988]
  50. Glob Health Sci Pract. 2018 Jun 29;6(2):384-389 [PMID: 29875157]
  51. Fly (Austin). 2012 Apr-Jun;6(2):80-92 [PMID: 22728672]
  52. Sci Rep. 2022 Nov 18;12(1):19845 [PMID: 36400806]
  53. Int J Environ Res Public Health. 2018 Nov 27;15(12): [PMID: 30486449]
  54. BMC Genet. 2010 Oct 15;11:94 [PMID: 20950446]
  55. PLoS Negl Trop Dis. 2016 Jan 14;10(1):e0004376 [PMID: 26766548]
  56. Ann N Y Acad Sci. 2015 Apr;1342:10-8 [PMID: 25694157]
  57. Am J Trop Med Hyg. 2021 Jan;104(1):263-270 [PMID: 33289466]
  58. Bio Protoc. 2023 Mar 05;13(5):e4621 [PMID: 36908639]
  59. Malar J. 2021 Feb 12;20(1):88 [PMID: 33579285]
  60. PLoS One. 2022 Nov 22;17(11):e0273872 [PMID: 36413547]
  61. Evolution. 1984 Nov;38(6):1358-1370 [PMID: 28563791]
  62. Am J Trop Med Hyg. 2018 Jul;99(1):73-83 [PMID: 29741155]
  63. Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0009521 [PMID: 34031050]
  64. PLoS Negl Trop Dis. 2019 Nov 11;13(11):e0007876 [PMID: 31710604]
  65. Pathogens. 2023 May 17;12(5): [PMID: 37242401]
  66. Lancet Reg Health Am. 2023 Jan 02;18:100420 [PMID: 36844008]
  67. Int J Parasitol Drugs Drug Resist. 2021 Aug;16:23-37 [PMID: 33957488]
  68. Trans R Soc Trop Med Hyg. 1999 Jul-Aug;93(4):369-74 [PMID: 10674079]
  69. PLoS Negl Trop Dis. 2024 Jul 11;18(7):e0011879 [PMID: 38991038]

Grants

  1. G.0A42.22N/Fonds Wetenschappelijk Onderzoek
  2. PE2018TEA470A102/VLIR-UOS, Belgium
  3. 165-2020-FONDECYT/Consejo Nacional de Ciencia, Tecnología e Innovación Tecnológica
  4. U19 AI089681/NIAID NIH HHS
  5. FA4 Peru (2017 - 2021)/Belgium Development Cooperation (DGD)
  6. 5U19AI089681-15/NIH HHS
  7. P0134_23_N6/Armed Forces Health Surveillance Division (AFHSD-GEIS)
  8. FA5 Peru (2022 - 2026)/Belgium Development Cooperation (DGD)

MeSH Term

Peru
Humans
Plasmodium falciparum
Plasmodium vivax
Malaria, Falciparum
Malaria, Vivax
Protozoan Proteins
Female
Male
Child
Adult
Antimalarials
Adolescent
Drug Resistance
Middle Aged
Indigenous Peoples
Young Adult
Child, Preschool
Genomics
Genetic Variation
Antigens, Protozoan

Chemicals

Protozoan Proteins
Antimalarials
Antigens, Protozoan

Word Cloud

Created with Highcharts 10.0.0PfparasitesPvmalariatransmissionareasNJremotePeruvianpopulationresistanceAmazononediversityeliminationdeletionsNuevaindigenouscommunitymobilitysamples2020ACDdetectionusingonesgeneticspersistentdetectedHe = 0outbreakMoreoverFst = 0MalariaHard-to-reachcommunitiesrepresentPeru'smainchallengeinformationscarceassessedPlasmodiumvivaxPfalciparumdynamicsmarkershrp2/3JerusalénhighcollectedNovember2019MayactivepassivecasePCDParasitesidentifiedmicroscopyPCRanalyzedrepresentativesetpositive-PCRPv = 68Pf = 58highly-multiplexeddeepsequencingassaysAmpliSeqcomparedindexesinterventionreducecasesshorttermobservedleastinfection96%studydaysJerusalenmodestgenetic27lower08presentedtemporalclusteringclusterslinkedFebruaryexhibitedvariablelevelsdifferentiation07-05211-058artemisinmutationschloroquine57%sulfadoxine-pyrimethamine35-67%NJ'spfhrp2/3genecommon32-50%genesdeletedgeneticallydistinctlocalhighlightneedtailoredinterventionsfocusingpatternsimportedinfectionseliminateGenomicsurveillanceDrugGeneticHRP2persistencePopulation

Similar Articles

Cited By